EW

NYSE:EW

Edwards Lifesciences Corporation

Add to Watchlist
  • Stock

75.18

−0.41%

−2.98

USD last updated 11/08 02:03:55

Last Close

78.16

11/08 22:30

Market Cap

56.51B

Beta: 1.01

Volume Today

3.88M

Avg: 3.25M

PE Ratio

36.59

PFCF: 66.37

The global Vital Signs Monitoring Devices market was valued at US$5.35 billion in 2023 and reached US$5.73 billion in 2024, with projections indicating it will grow to US$11.12 billion by 2033 at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033. Key drivers include rising chronic disease prevalence, technological advancements such as AI and wireless connectivity, increased remote patient monitoring, an aging population, growing health awareness, and supportive government policies. North America leads the market, followed by Europe, with strong growth expected in Asia-Pacific, Latin America, and the Middle East and Africa. Major players include Koninklijke Philips N.V., Medtronic Nihon Kohden Corporation, GE Healthcare, Masimo Corporation, Omron Healthcare, Contec Medical Systems Co., Ltd., A&D Company Ltd., Nonin Medical Inc., and SunTech Medical, Inc. Recent developments include Cardinal Health launching the Kendall DLTM Multi System, Apple's expected launch of the Apple Watch Series 11 with blood pressure monitoring, Medtronic's launch of the CorsanoTM wearable, and Edwards Lifesciences selling its critical care products unit to Becton Dickinson for $4.2 billion.

openpr.com

Benjamin Edwards Inc. reduced its stake in Northern Trust Corporation by 6.6% in the first quarter, selling 5,167 shares and holding 73,016 shares valued at $7.2 million. Other institutional investors also adjusted their positions, with Massachusetts Financial Services Co. MA increasing holdings by 4.9%, Bank of New York Mellon Corp by 47.8%, UBS AM by 9.5%, Royal Bank of Canada by 60.2%, and Dimensional Fund Advisors LP increasing by 2.9% in the fourth quarter. Eighty-three point one nine percent of Northern Trust's stock is held by hedge funds and institutional investors. The company declared a quarterly dividend of $0.80 per share, resulting in an annual yield of 2.5% and a payout ratio of 35.25%. Northern Trust reported earnings per share of $2.13, exceeding expectations of $2.08, despite a 26.4% year-over-year revenue decline to $2 billion. The firm achieved a return on equity of 14.06% and a net margin of 11.75%. Wall Street analysts provided mixed ratings, with Keefe, Bruyette & Woods downgrading to 'underperform' at $118.00, Barclays raising to $136.00, Wells Fargo to $120.00, and Evercore ISI to $121.00. The consensus target price is $116.58 with an average rating of 'Hold'. Northern Trust operates in Asset Servicing and Wealth Management segments, offering global custody, fund administration, and investment management services. The stock has a market cap of $24.03 billion, P/E ratio of 14.76, PEG ratio of 1.67, and beta of 1.28. Its price range over one year is $81.62 to $133.00, with 50-day and 200-day moving averages at $121.43 and $108.70, respectively. The stock opened up 0.7% at $125.65 on Friday, and has a debt-to-equity ratio of 0.58 and current ratio of 0.72.

marketbeat.com

Benjamin Edwards Inc. increased its ownership of Tractor Supply Company (TSCO) by 16.6% in the first quarter, holding 1,010,704 shares valued at $55.7 million, or 0.19% of the company's stock. Tractor Supply reported a quarterly EPS of $0.81, exceeding estimates, with $4.44 billion in revenue, up 4.5% year-over-year. The company announced a $0.23 quarterly dividend, yielding 1.6%, with an annualized payout of $0.92 and a payout ratio of 45.10%. It has a market cap of $31.42 billion, a P/E ratio of 29.08, a PEG ratio of 3.09, and a beta of 0.75. The stock traded between $46.85 and $63.99 over the past year, with 50-day and 200-day moving averages at $55.02 and $53.71, respectively. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.16, and a current ratio of 1.28. Insiders including Executive Vice President and Director Denise L. Jackson sold shares, reducing their positions by 14.27% and 11.60% respectively, with total insider sales over 90 days amounting to 207,490 shares worth $12.22 million. Analyst ratings were updated, with Loop Capital, Evercore ISI, Telsey Advisory Group, Citigroup, and Piper Sandler adjusting price targets to $60.00, $65.00, $70.00, $51.00, and $67.00, respectively, and the average target price now at $61.80. Tractor Supply is a rural lifestyle retailer in the U.S., offering livestock, pet, recreation, hardware, and lifestyle products.

marketbeat.com

The FDA announced the launch of a PreCheck program to streamline domestic drug manufacturing and reduce reliance on foreign sources, in response to President Trump's Executive Order 14293. The program includes facility readiness and application submission phases to improve regulatory predictability. The agency also named Sean Keveney as its new chief counsel, following his role as acting general counsel at HHS. Robert Foster, HHS principal deputy general counsel, will take over as acting general counsel at HHS. HHS terminated 22 mRNA vaccine projects by BARDA due to concerns over efficacy against upper respiratory infections, with HHS Secretary Robert Kennedy Jr. citing data showing insufficient protection. Experts, including AMA president Bobby Mukkamala, have criticized the decision. The FTC blocked Edwards Lifesciences from acquiring JenaValve Technology, citing reduced competition in TAVR-AR devices. Former FDA Commissioner David Kessler has supported Kennedy Jr.'s push to regulate ultraprocessed foods, filing a citizen petition. FDA lifted a pause on Valneva Austria GmbH's Ixchiq vaccine for patients over 60, after concluding an investigation into adverse events. The FDA conducted 989 drug quality assurance inspections in FY 2024, a 27% increase from the prior year, and reported 63 biosimilar products in its catalog, a 47% increase. Jazz Pharmaceuticals' Modeyso was accelerated approved for treating H3 K27M-mutant diffuse midline glioma. FDA also introduced a new website on PFAS use in medical devices, asserting that fluoropolymers used are too large to cross cell membranes and are unlikely to be toxic. Early warnings were issued for Boston Scientific's Endotak Reliance defibrillation leads and Watchman Access Systems due to risks of calcification and air embolism, respectively.

raps.org

The Federal Trade Commission (FTC) has filed a complaint to block Edwards Lifesciences' proposed $945 million acquisition of JenaValve Technology, Inc., arguing that the deal would eliminate competition in the U.S. market for transcatheter aortic valve replacement devices designed to treat aortic regurgitation (TAVR-AR). The FTC claims that Edwards already owns JC Medical, the other major TAVR-AR developer, and acquiring JenaValve would consolidate the two leading competitors, potentially stifling innovation, reducing product quality, and increasing prices. The agency asserts that direct competition between JenaValve and JC Medical has driven progress in clinical development and product improvements. The FTC has voted unanimously to issue an administrative complaint and seek a temporary restraining order and preliminary injunction to halt the transaction.

mychesco.com

    Description

    Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to trea...Show More

    Earnings

    Earnings per Share (Estimate*)

    0.10.20.30.40.50.60.72017-04-252019-04-232021-04-202023-04-262024-10-24

    Revenue (Estimate*)

    500M1B1.50B2017-04-252019-04-232021-04-202023-04-262024-10-24

    *Estimate based on analyst consensus